Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy

Authors:
  • SCSophie Le Coeur
    Sophie Le Coeur
  • CBChureeratana Bowonwatanuwong
    Chureeratana Bowonwatanuwong
  • PKPacharee Kantipong
    Pacharee Kantipong
  • PLPranee Leechanachai
    Pranee Leechanachai
  • SASurabhon Ariyadej
    Surabhon Ariyadej
  • PLPrattana Leenasirimakul
    Prattana Leenasirimakul
  • SHScott Hammer
    Scott Hammer
  • MLMarc Lallemant
    Marc Lallemant
  • PGPerinatal HIV Prevention Trial Group
    Perinatal HIV Prevention Trial Group

Abstract
A single intrapartum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV) leads to the selection of resistance mutations. Whether there are clinically significant consequences in mothers who are subsequently treated with a nevirapine-containing regimen is unknown.

This publication has 13 references indexed in Scilit: